Search results :

Conjugated estrogens

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: G03CA57

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9
Pruritus postmarketing, 0.714% - 5.03% 0% - 2.11% x x x x x x x x
Breast pain 2.14% - 4.9% 0% - 4.17% x x x x x x x
Vulvovaginal disorder 2.14% - 2.8% 0% - 2.94% x
Vasodilation 1.43% - 2.1% 0% - 2.78% x
Candida infection 0.714% - 1.4% 0% - 1.39% x
Vaginal haemorrhage 0.714% - 1.4% 0% - 1.47% x x x x x x x
Acne 0% - 1.43% 0% x
Dysuria 0% - 1.4% 0% x x
Cramp muscle 0% - 1.4% 0% x x
Micturition urgency 0% - 0.699% 0% - 1.39% x
Breast enlargement 0% - 0.699% 0% - 1.39% x x
Abdominal cramps postmarketing x x x x x x x
Abdominal pain postmarketing 9.72% x x x x x x x x
Arthralgia postmarketing x x x x x x x x
Breast cancer postmarketing x x
Vaginal moniliasis postmarketing, 0% - 1.4% 0% x x x x x x x x
Cystitis postmarketing x x
Depression postmarketing x x x x x x x x x
Dizziness postmarketing, 0% - 0.699% 0% - 4.17% x x x x x x x x x
Dysmenorrhoea postmarketing 2.78% x x x x x x x x x
Oedema postmarketing x x x x x x x x x
Endometrial hyperplasia postmarketing x x x x x x x x
Epilepsy postmarketing x x x x x x x
Erythema multiforme postmarketing x x x x x x x x
Erythema nodosum postmarketing x x x x x x x x
Rash postmarketing x x x x x x x x
Fibrocystic breast disease postmarketing x x x x x x x x
Gallbladder disorder postmarketing x x x x x x x x x
Gynaecomastia postmarketing x x
Headache postmarketing, 2.14% - 3.5% 1.39% - 20.8% x x x x x x x x x
Haemangioma postmarketing x x x x x x x
Hirsutism postmarketing x x x x x x x x x
Hypersensitivity postmarketing x x
Irritability postmarketing x x x x x x x x
Jaundice cholestatic postmarketing x x x x x x x x
Cramps of lower extremities postmarketing x x x x x x x x
Leukorrhea postmarketing, 2.1% - 2.86% 1.39% - 7.35% x x x x
Chloasma postmarketing x x x x x x x x x
Myocardial infarction postmarketing x x x x x x x x
Nausea postmarketing 8.33% x x x x x x x x x
Nervousness postmarketing x x x x x x x x x
Pain postmarketing, 0.714% - 1.4% 0% - 8.33% x x
Pancreatitis postmarketing x x x x x x x
Pelvic pain postmarketing, 2.8% - 2.86% 0% - 2.78% x x x x x
Porphyrin metabolism disorder postmarketing x x x x x x x
Pruritus genital postmarketing x
Precocious puberty postmarketing x
Pulmonary embolism postmarketing x x x x x x x x
Cerebrovascular accident postmarketing x x x x x x x x
Thrombophlebitis postmarketing x x x x x x x x
Urticaria postmarketing x x x x x x x x
Uterine leiomyoma postmarketing x x x x x x x x
Uterine haemorrhage postmarketing x x
Vaginal inflammation postmarketing, 1.4% - 2.14% 1.39% - 4.41% x x x x x x x x
Vomiting postmarketing x x x x x x x x x
Deep vein thrombosis postmarketing x
Migraine postmarketing, 0% 0% - 1.47% x x x x x x x x x
Colitis ischaemic postmarketing x x x x
Tenderness postmarketing x x x x x x x x
Superficial phlebothrombosis postmarketing x x x x x x x
Galactorrhoea postmarketing x x x x x x x
Glucose tolerance impaired postmarketing x x x x x
Meningioma benign postmarketing x x x x
Exacerbation of asthma postmarketing x x x x x x x x
Endometrial cancer postmarketing x x x x x x x x
Blood pressure increased postmarketing x x x x x x x x x
Dementia postmarketing x x x x x x x x
Vulvovaginal discomfort postmarketing x
Retinal vascular thrombosis postmarketing x x x x x x x x
Ovarian cancer postmarketing x x x x x x x
Abdominal bloating postmarketing x x x x x x x x x
Mood alteration NOS postmarketing x x x x x x x
Anaphylactic shock x x x x x
Angioedema x x x x x
Asthenia x x x
Back pain x x x
Clotting x
Breast swelling x
Bronchitis 4.17% x x x
Neoplasm malignant x x
Cardiovascular disorder x
Uterine cervical erosion x
Chorea x x x x x x
Infection x x x
Coronary artery thrombosis x
Diarrhoea x x x
Dyspepsia x x x
Dyspnoea x
Endometriosis x
Epistaxis x
Fatigue x
Flatulence 2.78% x x x x x x
Hyperglycaemia x
Hypernatraemia x
Hypocalcaemia x x x x x x
Influenza 4.17% x x x x x x
Jaundice x
Leg pain x
Hepatic neoplasm x
Menorrhagia x
Metrorrhagia 0% 0% - 2.94% x x x x x
Musculoskeletal pain x
Neuritis x
Numbness x
Optic neuritis x
Palpitations x
Paraesthesia 0% x x x
Pharyngitis x x x
Phlebitis x
Rhinitis 5.56% x x x x x x
Sinusitis 2.78% x x x x x x
Swelling x
Syncope x
Thromboembolism x
Thrombosis x
Erythema 0% 0% - 1.39% x
Upper respiratory tract infection x x x
Pollakiuria 0% 0% - 1.39% x
Urinary tract infection 0% 0% - 1.39% x
Vaginal itching x
Varicose vein x
Hepatic function abnormal x
Breast discharge x x x
Injection site swelling x
Glucose tolerance decreased x
Accidental injury 6.94% x x x x x x
Injection site pain x
Skin irritation x
Myalgia x x x
Abdominal discomfort x
Abdominal pain upper x
Abdominal pain lower x
Dermatitis hemorrhagic x x x x x x x
Breast tenderness x x
Fluid retention x
Ectropion of cervix x x x x x x
Increased tendency to bruise x
Pre-existing disease x x x
Visual disturbance x
Cough increased x x x
Mass x
Breast discomfort x
Insomnia x x x
Abnormal withdrawal bleeding x x x
Bleeding breakthrough x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

CONJUGATED ESTROGENS / PMS-CONJUGATED ESTROGENS C.S.D.

Side effects:66
Source:Health Canada

ESTROGENS, CONJUGATED

Side effects:65
Source:FDA Structured Product Label

ESTROGENS, CONJUGATED

Side effects:56
Source:FDA Structured Product Label

ESTROGENS, CONJUGATED SYNTHETIC B

Side effects:66
Source:FDA Structured Product Label

ESTROGENS, CONJUGATED

Side effects:73
Source:FDA Structured Product Label

ESTROGENS, CONJUGATED

Side effects:76
Source:FDA Structured Product Label

ESTROGENS, CONJUGATED

Side effects:76
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label